Breast Health, Hormones, and Knowing Your Risk: What Every Woman Should Understand

Breast health is one of those topics that generates a lot of anxiety and, unfortunately, a lot of misinformation. Women are often told when to get a mammogram but rarely given the context to understand what screening can and cannot tell them, how their individual risk profile shapes those decisions, or how hormones actually relate to breast cancer risk.

At Valley Vital Medicine in Fargo, ND, Kali Boyer, FNP-C, our women’s health nurse practitioner, recently walked through all of it in depth. This post draws from that presentation to give you a clear, honest, evidence-grounded overview so you can feel genuinely informed walking into your next healthcare conversation.

Why Breast Health Deserves Your Attention

One in eight women in the United States will be diagnosed with breast cancer in her lifetime. It is the most common cancer in women both in the U.S. and globally, and the second leading cause of cancer death in women after lung cancer. The reason early detection receives so much emphasis is straightforward: finding breast cancer early significantly expands treatment options and lowers mortality.

But screening is not one-size-fits-all, and understanding where you fall on the risk spectrum is the first step to making good decisions about your own care.

Understanding Your Individual Risk

Some breast cancer risk factors cannot be changed. Being female accounts for 99.5% of diagnoses. Risk increases with age, with most cancers occurring in women over 55 and the average age of diagnosis around 61. Early menstruation (before age 11), late menopause (after 55), having a first full-term pregnancy after 30 or never having a full-term pregnancy, and shorter or no breastfeeding duration are all associated with elevated risk. High breast density, which can only be identified on a mammogram and has nothing to do with breast size or firmness, also increases risk. Approximately 5 to 10% of breast cancers are hereditary, most commonly linked to BRCA1 and BRCA2 gene mutations.

Other risk factors are within your control. Obesity increases breast cancer risk, particularly after menopause, and breast cancers in women with obesity tend to be more aggressive. Alcohol consumption raises risk in a dose-dependent way, meaning the more you drink, the higher the risk. Physical inactivity, smoking, use of synthetic progestins (not to be confused with bioidentical progesterone, which we will discuss shortly), and diets high in sugar and processed foods are all modifiable risk factors.

Understanding which category you fall into matters because your screening plan should reflect it. Average-risk women have no personal history of breast cancer, no strong family history, no known high-risk gene mutation, and no chest radiation before age 30. Women with additional risk factors, such as a first-degree relative with breast cancer or confirmed dense breast tissue, may fall into an intermediate category. High-risk designation generally applies to women with a lifetime breast cancer risk greater than 20%, a known BRCA1 or BRCA2 mutation (or a first-degree relative with one who has not yet been personally tested), chest radiation before 30, or certain hereditary conditions. Women in the high-risk category typically have more intensive screening recommendations, including annual mammograms and breast MRI starting at age 30.

Screening Tools: What They Can and Cannot Tell You

No screening test is perfect. Every tool has benefits and limitations, and understanding both is part of making an informed decision.

Mammography remains the gold standard for breast cancer screening because the evidence supporting its role in reducing breast cancer mortality is the strongest we have. A standard screening mammogram delivers approximately 0.4 millisieverts of radiation, roughly equivalent to the natural background radiation a person receives in 48 days of everyday life. Single doses below 50 millisieverts are considered very low risk with no clear scientific link to increased breast cancer incidence. Modern 3D mammograms (tomosynthesis) have lower callback rates and higher cancer detection rates, particularly in women with dense breast tissue.

Screening guidelines vary slightly across major medical organizations, but most recommend average-risk women begin annual or biennial mammograms at age 40. The American Cancer Society suggests annual screening from 45 to 54, with the option to transition to every two years at 55. ACOG recommends every one to two years starting at 40. The NCCN recommends annually. The USPSTF recommends every two years. The most consistent message across all organizations: start at 40.

Limitations of mammography include discomfort, lower sensitivity in women with dense breast tissue (where dense tissue can obscure findings), false negatives (approximately one in eight breast cancers may be missed), and false positives (about half of women who screen annually for ten years will have at least one false positive leading to additional imaging or biopsy). A normal mammogram does not mean any new breast symptom should be ignored. Any new lump, skin change, nipple discharge, or unexplained breast pain warrants evaluation regardless of when your last mammogram was.

Breast density is worth understanding on its own. About half of women over 40 have dense breast tissue. It is categorized on a scale from A (almost entirely fatty) to D (extremely dense). Denser tissue is associated with higher cancer risk and also makes mammograms harder to read, since both dense tissue and tumors appear white. The FDA requires mammogram reports to indicate whether dense breast tissue is present.

Thermography, also called digital infrared thermal imaging, uses an infrared camera to detect temperature differences and blood flow patterns near the breast surface. The theory is that increased blood flow or temperature may indicate tumor activity. The FDA has authorized thermography as an adjunct to mammography, not as a replacement or standalone screening method. The current evidence does not support it as a substitute for mammography. If you choose to use thermography, doing so between regular mammograms, rather than in place of them, is a reasonable approach that adds visual information without replacing the standard with the stronger evidence base.

QT Imaging is a newer option worth watching. It is a 3D breast acoustic CT using quantitative transmission ultrasound, involving no radiation, no breast compression, and no contrast dye. The breast rests in warm water while a scanner rotates to create a three-dimensional image. Early evidence shows promise for fewer unnecessary callbacks and better characterization of dense breast tissue. The FDA has cleared it as an add-on, not a replacement for mammography. Larger independent trials are still needed, but it represents a potentially significant advancement in patient-friendly breast imaging.

Cancer Screening Blood Tests Offered at Valley Vital Medicine

Valley Vital Medicine offers two RGCC liquid biopsy tests as part of an integrative cancer screening and monitoring approach.

OncoDeclare (also called Onco-D-Clare) is a blood-based cancer screening test that analyzes the gene expression of more than 90 genes in immune cells. It does not look for tumor cells directly. Instead, it measures how your immune system is responding at a molecular level. A positive result suggests the immune system may be responding to early cancer activity, potentially before symptoms appear or conventional imaging detects a change. RGCC, the company behind the test, reports approximately 93% accuracy in their clinical validation. It is important to note that this figure reflects the company’s own internal validation, and independent peer-reviewed data in large general populations is still limited. A positive OncoDeclare result is considered reversible with lifestyle intervention, making it a potential tool for early action rather than confirmed diagnosis.

OncoTrace goes further. It detects circulating tumor cells and circulating cancer stem cells in the blood, measures stemness markers that may reflect how aggressive or treatment-resistant the cancer cells are, and identifies tissue-of-origin markers to suggest where the cancer may have originated. OncoTrace is most appropriate for women with a current or prior cancer diagnosis, used alongside conventional oncology care to monitor treatment response and progression. A positive OncoDeclare is reversible through lifestyle change; a positive OncoTrace means cancer is already present, and the focus shifts to treatment tracking.

Both tests are offered as complementary tools alongside, not in place of, conventional screening methods.

Hormones and Breast Health: Clearing Up Decades of Confusion

The fear that hormone therapy causes breast cancer has shaped women’s healthcare for over two decades, and it traces back almost entirely to one study and one moment of media misrepresentation.

In 2002, the Women’s Health Initiative published findings that created widespread panic about hormone therapy. What the headlines failed to communicate: the women in the study averaged around 63 years of age, most were already 10 or more years past menopause, many were overweight, had high blood pressure, or had other preexisting conditions. The hormones used were synthetic conjugated equine estrogens and medroxyprogesterone acetate (a synthetic progestin), not bioidentical hormones. The increased breast cancer finding was seen in the estrogen-plus-synthetic-progestin arm of the study, involving fewer than 1% of participants annually. The estrogen-only arm of the same study was later found to be associated with a 23% reduction in breast cancer risk and a 40% reduction in breast cancer mortality.

When the data was reexamined more thoroughly in the years that followed, researchers concluded that synthetic progestin, not estrogen, was the likely driver of the elevated risk. Bioidentical progesterone, which is molecularly identical to what the body produces naturally, has not been shown to carry the same risk profile as synthetic progestins.

The broader picture on estrogen: it may be breast-protective. Loss of estrogen is associated with increased breast cancer risk in some research. Neither estrogen nor estradiol (the bioidentical form) have been found to increase breast cancer risk, and some studies indicate a protective effect.

Testosterone also appears to be breast-protective. Research suggests testosterone may decrease tissue proliferation in breast cells. Studies on pharmacological testosterone doses delivered via subcutaneous pellets, including research from Dr. Rebecca Glazer, a former breast cancer surgeon who now focuses her practice on testosterone pellet therapy, have shown reduced incidence of breast cancer and no association with recurrence in breast cancer survivors. Men, who have significantly higher androgen levels than women, represent less than 1% of breast cancer diagnoses. The progressive loss of testosterone beginning at around age 30 leaves women with increasingly insufficient androgen support, which may itself carry health consequences.

Not all hormone therapies are equivalent. Bioidentical hormones are structurally identical to what the body produces. Synthetic versions are different, and their risk profiles differ as well. Route of administration also matters. Oral estrogen, for example, has been associated with increased clotting risk because it passes through the liver. Transdermal and pellet delivery methods bypass the liver and carry a different safety profile.

If you have been told by a provider that hormone therapy is not safe for you, especially if the reason given was a family history of breast cancer, that conversation may be worth revisiting with someone who is current on the evidence. Kali and Trevor at Valley Vital Medicine have both completed advanced hormone therapy training and are equipped to walk through your individual history and risk profile in detail.

Practical Breast Health: What You Can Do Now

Lifestyle factors that may reduce breast cancer risk include maintaining a healthy body weight, regular physical activity, limiting or eliminating alcohol, avoiding smoking, eating a whole-food diet with limited sugar and processed food, supporting gut health, and reducing exposure to environmental estrogen disruptors like BPA.

If you breastfed or had children at a younger age, research suggests those experiences may be modestly protective, likely because they cause breast cells to mature more fully and may help clear damaged DNA from breast tissue during periods of lactation.

Knowing your own breasts matters too. Rather than a rigid monthly self-exam schedule, what matters is knowing what is normal for you so you can recognize when something changes. Skin dimpling, swelling, redness, thickening around the nipple, nipple retraction, unusual discharge, a new lump or mass, unexplained breast pain or tenderness, and swollen lymph nodes under the arm or near the collarbone are all changes that warrant evaluation promptly, not in a few weeks.

How to Get Started

If you have questions about your breast cancer risk, want to understand your hormone options, or are interested in OncoDeclare or OncoTrace screening, Kali Boyer, FNP-C, offers individualized women’s health appointments at Valley Vital Medicine, often with same-day availability.

For a broader health conversation, our certified health coach Lori is available for a free discovery call where you can talk through your concerns and goals and determine the right starting point for your care.

Call 701-532-1926 or visit www.valleyvitalmedicine.com/contact-us to schedule.

Medical Disclaimer: The information in this article is for educational purposes only and does not constitute medical advice. Breast cancer screening and hormone therapy decisions should be made in partnership with a qualified healthcare provider based on your individual health history, risk factors, and preferences. OncoDeclare and OncoTrace are not FDA-cleared diagnostic tests and are not substitutes for standard breast cancer screening methods.

References:

1. American Cancer Society. Breast cancer screening guidelines for average-risk women. 2024.
2. American College of Obstetricians and Gynecologists. Breast cancer risk assessment and screening. 2024.
3. Chlebowski RT, et al. Estrogen alone in postmenopausal women: Women’s Health Initiative randomized trial update. J Natl Cancer Inst. 2015.
4. Glazer RD, et al. Subcutaneous testosterone and anastrozole: breast cancer prevention and hormone deficiency treatment in women. Maturitas. 2019.
5. Manson JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality. JAMA. 2017.
6. FDA. Mammography Quality Standards Act requirements on breast density reporting. Updated 2023.
7. RGCC International. OncoDeclare clinical validation summary. 2024.
8. QT Imaging. FDA 510(k) clearance and clinical evidence for breast acoustic CT. 2024.